Participant flow

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies · Source last updated 2021-07-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   INCAGN01876 in combination with pembrolizumab and epacadostat

   id

   FG000

   title

   INCAGN01876 + Pembrolizumab + Epacadostat

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Study Terminated By Sponsor

   2. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Withdrawal by Subject

   3. reasons

      1. group Id

         FG000

         num Subjects

         4

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         10

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         10

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

A total of 10 participants were screened and enrolled in the study.

recruitment Details

The study was conducted at 2 different sites in USA. A total of 10 participants were enrolled in the study.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice